Suppr超能文献

ESMO 管理和治疗适应 COVID-19 时代的建议:结直肠癌。

ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer.

机构信息

Charite Comprehensive Cancer Center, Charite Universitatsmedizin Berlin, Berlin, Germany.

Department of Hematology, Oncology and Tumor Immunology (CCM), Charite Universitatsmedizin Berlin, Berlin, Germany.

出版信息

ESMO Open. 2020 May;5(Suppl 3):e000826. doi: 10.1136/esmoopen-2020-000826.

Abstract

COVID-19 pandemic challenges health system capacities in many countries. National healthcare services have to manage unexpected shortage of healthcare resources that have to be reallocated according to the principles of fair and ethical prioritisation, in order to maintain the highest levels of care to all patients, ensure the safety of patients and healthcare workers and save as many lives as possible. Beyond that, cancer care services have to pursue restructuring, following the same evidence-based dispositions. In this article, we propose guidance to the management of colorectal cancer during the pandemic, prioritised according to a three-tiered framework, based on expert clinical judgement and magnitude of benefit expected from specific interventions. Since the availability of resources for diagnostic procedures, surgery and postoperative care, systemic therapy and radiotherapy may differ, authors did separate prioritisation analyses. The impact of postponing or abrogating cancer interventions on outcomes according to a high, medium or low priority scale, is outlined and discussed. The implementation of healthcare services using telemedicine is explored: it reveals itself as functional and effective for limiting patients' need to travel to centres and thereby has the potential to reduce diffusion of severe acute respiratory syndrome coronavirus 2. Colorectal cancer demands a considerable amount of medical resources. Therefore, the redefinition of its diagnostic and therapeutic algorithms with a rigorous method is crucial in order to ensure the highest quality of continuum of care in the broader context of the pandemic and the challenged healthcare systems.

摘要

COVID-19 大流行给许多国家的卫生系统能力带来了挑战。国家医疗保健服务必须管理医疗资源的意外短缺,并根据公平和伦理优先排序的原则进行重新分配,以维持对所有患者的最高水平的护理,确保患者和医护人员的安全,并尽可能挽救更多生命。除此之外,癌症护理服务也必须遵循相同的循证处置进行结构调整。在本文中,我们根据专家临床判断和预期从特定干预措施中获益的程度,提出了在大流行期间管理结直肠癌的指导意见,该指导意见基于三层框架进行优先级排序。由于诊断程序、手术和术后护理、系统治疗和放疗的资源可用性可能不同,作者分别进行了优先级分析。根据高、中、低优先级对推迟或取消癌症干预措施对结果的影响进行了概述和讨论。还探讨了使用远程医疗实施医疗服务的情况:它证明对于限制患者前往中心的需求是有效的,从而有可能减少严重急性呼吸系统综合症冠状病毒 2 的传播。结直肠癌需要大量的医疗资源。因此,需要用严格的方法重新定义其诊断和治疗算法,以确保在大流行和面临挑战的医疗体系的更广泛背景下,提供最高质量的连续护理。

相似文献

1
ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer.
ESMO Open. 2020 May;5(Suppl 3):e000826. doi: 10.1136/esmoopen-2020-000826.
2
ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.
ESMO Open. 2020 May;5(Suppl 3). doi: 10.1136/esmoopen-2020-000804.
4
Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.
Oncologist. 2020 Jul;25(7):e1013-e1020. doi: 10.1634/theoncologist.2020-0316. Epub 2020 May 26.
5
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.
ESMO Open. 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmoopen-2020-000793.
6
Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic.
Lancet Oncol. 2020 Jun;21(6):759-760. doi: 10.1016/S1470-2045(20)30278-3. Epub 2020 May 13.
7
Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: the new normal for breast cancer survivors?
Future Oncol. 2020 Oct;16(28):2191-2195. doi: 10.2217/fon-2020-0714. Epub 2020 Aug 28.
8
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer.
ESMO Open. 2020 Jun;5(Suppl 3). doi: 10.1136/esmoopen-2020-000820.
9
Cancer management challenge in a developing country in COVID-19 pandemic: reflection of a group of Moroccan oncologists.
Future Oncol. 2020 Sep;16(26):2007-2016. doi: 10.2217/fon-2020-0450. Epub 2020 Jun 25.
10
Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic.
Clin Cancer Res. 2020 Jul 1;26(13):3100-3103. doi: 10.1158/1078-0432.CCR-20-1364. Epub 2020 Apr 20.

引用本文的文献

3
Effect of aberrant fructose metabolism following SARS-CoV-2 infection on colorectal cancer patients' poor prognosis.
PLoS Comput Biol. 2024 Sep 27;20(9):e1012412. doi: 10.1371/journal.pcbi.1012412. eCollection 2024 Sep.
6
Telemedicine in Care of Sarcoma Patients beyond the COVID-19 Pandemic: Challenges and Opportunities.
Cancers (Basel). 2023 Jul 21;15(14):3700. doi: 10.3390/cancers15143700.
7
Can lymphocytes serve as a predictor of response to preoperative chemoradiation therapy for locally advanced rectal cancer?
Front Oncol. 2023 Apr 3;13:1138299. doi: 10.3389/fonc.2023.1138299. eCollection 2023.
10
Estimation of Oncologic Surgery Case Volume Before and After the COVID-19 Pandemic in France.
JAMA Netw Open. 2023 Jan 3;6(1):e2253204. doi: 10.1001/jamanetworkopen.2022.53204.

本文引用的文献

1
Caring for patients with cancer in the COVID-19 era.
Nat Med. 2020 May;26(5):665-671. doi: 10.1038/s41591-020-0874-8. Epub 2020 Apr 16.
2
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Nat Med. 2020 Apr;26(4):566-576. doi: 10.1038/s41591-020-0805-8. Epub 2020 Apr 6.
3
Fair Allocation of Scarce Medical Resources in the Time of Covid-19.
N Engl J Med. 2020 May 21;382(21):2049-2055. doi: 10.1056/NEJMsb2005114. Epub 2020 Mar 23.
5
A Novel Coronavirus from Patients with Pneumonia in China, 2019.
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
6
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
7
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.
9
ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310.
10
Myeloid suppressor cells in cancer and autoimmunity.
J Autoimmun. 2017 Dec;85:117-125. doi: 10.1016/j.jaut.2017.07.010. Epub 2017 Jul 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验